Literature DB >> 2045419

Immunoelectron microscopic localization of type 1 plasminogen activator inhibitor on the surface of activated endothelial cells.

R R Schleef1, D J Loskutoff, T J Podor.   

Abstract

Immunogold EM was employed to compare the distribution of type 1 plasminogen activator inhibitor (PAI-1) on the surface of agonist-activated human umbilical vein endothelial cells (HUVECs) with that of control, unactivated cells. As previously observed, (Schleef, R.R., T.J. Podor, E. Dunne, J. Mimuro, and D.J. Loskutoff. J. Cell Biol. 110:155-163), analysis of cross-sections of nonpermeabilized control HUVEC monolayers stained first with affinity-purified rabbit antibodies to PAI-1 and then with gold-conjugated goat anti-rabbit IgG, revealed the presence of relatively few gold particles (less than 1-2% of the total) on the apical cell surface. The majority of gold particles were detected primarily in the extracellular matrix between the culture substratum and the cell membrane. In contrast, treatment of HUVECs with tumor necrosis factor alpha (TNF alpha; 200 U/ml, 24 h) or with lipopolysaccharide (LPS; 10 micrograms/ml, 24 h) resulted in an increased staining of PAI-1 not only in the extracellular matrix, but also on the apical cell surface (10-fold increase). Immunoabsorption of the rabbit anti-PAI-1 with purified PAI-1, or treatment of HUVECs with tissue-type plasminogen activator (2.5 micrograms/ml, 2 h, 4 degrees C) reduced the amount of staining both on the apical surface and in the extracellular matrix of agonist-activated HUVECs by 80-95%. The topographical location of PAI-1 on the cell surface was examined further by coupling immunogold staining with high resolution surface replication. Transmission EM of surface replicas from TNF alpha- or LPS-activated HUVECs revealed a general increase in PAI-1 staining both on planar regions and within indentations of the apical cell surface. Nonactivated HUVECs revealed PAI-1-specific immunogold particles only in areas of exposed extracellular matrix between the cells and occasionally at regions of cell-cell contacts. Analysis of activated bovine aortic endothelial cells by immuno-electron microscopy, immunologic assays, and flow cytometry revealed similar increases in surface PAI-1. These increases in surface PAI-1 could be detected by 3 h and continued over a 24-h period. The expression of PAI-1 on the luminal surface of endothelial cells during immune or inflammatory reactions could reduce endothelial fibrinolytic activity, thus, promoting the localized, pathologic formation of intravascular thrombi.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2045419      PMCID: PMC2289026          DOI: 10.1083/jcb.113.6.1413

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  32 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers.

Authors:  A H Stolpen; E C Guinan; W Fiers; J S Pober
Journal:  Am J Pathol       Date:  1986-04       Impact factor: 4.307

3.  Quantitation and properties of the active and latent plasminogen activator inhibitors in cultures of human endothelial cells.

Authors:  E G Levin
Journal:  Blood       Date:  1986-05       Impact factor: 22.113

4.  Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity.

Authors:  P P Nawroth; D A Handley; C T Esmon; D M Stern
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

5.  Topography and dynamics of receptors for acetylated and malondialdehyde-modified low-density lipoprotein in the plasma membrane of mouse peritoneal macrophages as visualized by colloidal gold in conjunction with surface replicas.

Authors:  H Robenek; G Schmitz; G Assmann
Journal:  J Histochem Cytochem       Date:  1984-10       Impact factor: 2.479

6.  Characterization of two monoclonal antibodies against human tissue-type plasminogen activator.

Authors:  R R Schleef; M Sinha; D J Loskutoff
Journal:  Thromb Haemost       Date:  1985-04-22       Impact factor: 5.249

7.  Messenger RNA for plasminogen activator inhibitor.

Authors:  M Sawdey; T Ny; D J Loskutoff
Journal:  Thromb Res       Date:  1986-01-15       Impact factor: 3.944

8.  The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator.

Authors:  R R Schleef; T J Podor; E Dunne; J Mimuro; D J Loskutoff
Journal:  J Cell Biol       Date:  1990-01       Impact factor: 10.539

9.  Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells.

Authors:  J J Emeis; T Kooistra
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

10.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor.

Authors:  P P Nawroth; D M Stern
Journal:  J Exp Med       Date:  1986-03-01       Impact factor: 14.307

View more
  3 in total

1.  Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages.

Authors:  H Feldmann; H Bugany; F Mahner; H D Klenk; D Drenckhahn; H J Schnittler
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

2.  Impaired fibrinolysis in the hemolytic-uremic syndrome of childhood.

Authors:  D Menzel; M Levi; G Dooijewaard; M Peters; J W ten Cate
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

3.  Endothelial METTL3 (Methyltransferase-Like 3) Inhibits Fibrinolysis by Promoting PAI-1 (Plasminogen Activator Inhibitor-1) Expression Through Enhancing Jun Proto-Oncogene N6-Methyladenosine Modification.

Authors:  Qin Bai; Yao Lu; Yanhua Chen; Han Zhang; Weiwei Zhang; Huang Wu; Aiqing Wen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-10-14       Impact factor: 8.311

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.